ФарФаР - Фармацеутски факултет, репозиторијум
Универзитет у Београду, Фармацеутски факултет
    • English
    • Српски
    • Српски (Serbia)
  • Српски (ћирилица) 
    • Енглески
    • Српски (ћирилица)
    • Српски (латиница)
  • Пријава
Преглед записа 
  •   ФарФаР
  • Pharmacy
  • Radovi istraživača / Researchers’ publications
  • Преглед записа
  •   ФарФаР
  • Pharmacy
  • Radovi istraživača / Researchers’ publications
  • Преглед записа
JavaScript is disabled for your browser. Some features of this site may not work without it.

Association of moderate alpha-1 antitrypsin deficiency with lung cancer in the Serbian population

Само за регистроване кориснике
2006
Аутори
Topić, Aleksandra
Jelić-Ivanović, Zorana
Spasojević-Kalimanovska, Vesna
Spasić, Slavica M.
Чланак у часопису (Објављена верзија)
Метаподаци
Приказ свих података о документу
Апстракт
Background. Alpha-1 antitrypsin (AAT) is an important serine protease inhibitor in human plasma. Its major physiological role is to inhibit neutrophil elastase (NE) in the lower respiratory tract and protect lung tissue from destruction. Recent studies indicated an etiological role of NE in lung cancer development. The aim of this study was to investigate the association of alpha-1 antitrypsin deficiency (AATD) with lung cancer in patients with four different histological types of cancer: squamous cell carcinoma, adenocarcinomas, large cell carcinoma and small cell carcinoma. Methods. Phenotyping was carried out by isoelectric focusing (pH 4.2-4.9). We compared the frequency of AATD phenotypes in 186 lung cancer patients with the value obtained in our previous study in a healthy Serbian population (3.7%) using the Fisher exact test. Results. Allele frequencies in patients were Pi*M 0.9677, Pi*Z 0.0215, Pi*S 0.0081 and Pi*other rare 0.0027. Eleven of the 186 lung cancer patients (5.9%) ...were AATD heterozygotes with moderate deficiencies (PiMZ and PiMS). When this value was compared with AATD heterozygote frequency obtained in the healthy individuals (3.7%), the difference was close to the level of significance (p = 0.055). However, individuals with AATD phenotypes had a higher risk of developing squamous cell lung cancer then those with non-deficient AAT variants (OR = 4.51, 95% CI = 1.66-12.29). Conclusions. Our findings provide evidence of an association between AAT phenotypes with moderate deficiency and squamous cell lung cancer.

Кључне речи:
serine protease inhibitors / alpha-1 antitrypsin deficiency / lung cancer / neutrophil elastase
Извор:
Archives of Medical Research, 2006, 37, 7, 866-870
Издавач:
  • Elsevier Science Inc, New York
Финансирање / пројекти:
  • Испитивање биохемијских и генетичких фактора ризика као узрочника и маркера атеросклерозе и других обољења: аналитички и клинички аспекти (RS-145036)

DOI: 10.1016/j.arcmed.2006.05.006

ISSN: 0188-4409

PubMed: 16971227

WoS: 000240894300010

Scopus: 2-s2.0-33748794783
[ Google Scholar ]
15
14
URI
https://farfar.pharmacy.bg.ac.rs/handle/123456789/705
Колекције
  • Radovi istraživača / Researchers’ publications
Институција/група
Pharmacy
TY  - JOUR
AU  - Topić, Aleksandra
AU  - Jelić-Ivanović, Zorana
AU  - Spasojević-Kalimanovska, Vesna
AU  - Spasić, Slavica M.
PY  - 2006
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/705
AB  - Background. Alpha-1 antitrypsin (AAT) is an important serine protease inhibitor in human plasma. Its major physiological role is to inhibit neutrophil elastase (NE) in the lower respiratory tract and protect lung tissue from destruction. Recent studies indicated an etiological role of NE in lung cancer development. The aim of this study was to investigate the association of alpha-1 antitrypsin deficiency (AATD) with lung cancer in patients with four different histological types of cancer: squamous cell carcinoma, adenocarcinomas, large cell carcinoma and small cell carcinoma. Methods. Phenotyping was carried out by isoelectric focusing (pH 4.2-4.9). We compared the frequency of AATD phenotypes in 186 lung cancer patients with the value obtained in our previous study in a healthy Serbian population (3.7%) using the Fisher exact test. Results. Allele frequencies in patients were Pi*M 0.9677, Pi*Z 0.0215, Pi*S 0.0081 and Pi*other rare 0.0027. Eleven of the 186 lung cancer patients (5.9%) were AATD heterozygotes with moderate deficiencies (PiMZ and PiMS). When this value was compared with AATD heterozygote frequency obtained in the healthy individuals (3.7%), the difference was close to the level of significance (p = 0.055). However, individuals with AATD phenotypes had a higher risk of developing squamous cell lung cancer then those with non-deficient AAT variants (OR = 4.51, 95% CI = 1.66-12.29). Conclusions. Our findings provide evidence of an association between AAT phenotypes with moderate deficiency and squamous cell lung cancer.
PB  - Elsevier Science Inc, New York
T2  - Archives of Medical Research
T1  - Association of moderate alpha-1 antitrypsin deficiency with lung cancer in the Serbian population
VL  - 37
IS  - 7
SP  - 866
EP  - 870
DO  - 10.1016/j.arcmed.2006.05.006
ER  - 
@article{
author = "Topić, Aleksandra and Jelić-Ivanović, Zorana and Spasojević-Kalimanovska, Vesna and Spasić, Slavica M.",
year = "2006",
abstract = "Background. Alpha-1 antitrypsin (AAT) is an important serine protease inhibitor in human plasma. Its major physiological role is to inhibit neutrophil elastase (NE) in the lower respiratory tract and protect lung tissue from destruction. Recent studies indicated an etiological role of NE in lung cancer development. The aim of this study was to investigate the association of alpha-1 antitrypsin deficiency (AATD) with lung cancer in patients with four different histological types of cancer: squamous cell carcinoma, adenocarcinomas, large cell carcinoma and small cell carcinoma. Methods. Phenotyping was carried out by isoelectric focusing (pH 4.2-4.9). We compared the frequency of AATD phenotypes in 186 lung cancer patients with the value obtained in our previous study in a healthy Serbian population (3.7%) using the Fisher exact test. Results. Allele frequencies in patients were Pi*M 0.9677, Pi*Z 0.0215, Pi*S 0.0081 and Pi*other rare 0.0027. Eleven of the 186 lung cancer patients (5.9%) were AATD heterozygotes with moderate deficiencies (PiMZ and PiMS). When this value was compared with AATD heterozygote frequency obtained in the healthy individuals (3.7%), the difference was close to the level of significance (p = 0.055). However, individuals with AATD phenotypes had a higher risk of developing squamous cell lung cancer then those with non-deficient AAT variants (OR = 4.51, 95% CI = 1.66-12.29). Conclusions. Our findings provide evidence of an association between AAT phenotypes with moderate deficiency and squamous cell lung cancer.",
publisher = "Elsevier Science Inc, New York",
journal = "Archives of Medical Research",
title = "Association of moderate alpha-1 antitrypsin deficiency with lung cancer in the Serbian population",
volume = "37",
number = "7",
pages = "866-870",
doi = "10.1016/j.arcmed.2006.05.006"
}
Topić, A., Jelić-Ivanović, Z., Spasojević-Kalimanovska, V.,& Spasić, S. M.. (2006). Association of moderate alpha-1 antitrypsin deficiency with lung cancer in the Serbian population. in Archives of Medical Research
Elsevier Science Inc, New York., 37(7), 866-870.
https://doi.org/10.1016/j.arcmed.2006.05.006
Topić A, Jelić-Ivanović Z, Spasojević-Kalimanovska V, Spasić SM. Association of moderate alpha-1 antitrypsin deficiency with lung cancer in the Serbian population. in Archives of Medical Research. 2006;37(7):866-870.
doi:10.1016/j.arcmed.2006.05.006 .
Topić, Aleksandra, Jelić-Ivanović, Zorana, Spasojević-Kalimanovska, Vesna, Spasić, Slavica M., "Association of moderate alpha-1 antitrypsin deficiency with lung cancer in the Serbian population" in Archives of Medical Research, 37, no. 7 (2006):866-870,
https://doi.org/10.1016/j.arcmed.2006.05.006 . .

DSpace software copyright © 2002-2015  DuraSpace
О ФарФаР-у | Пошаљите запажања

OpenAIRERCUB
 

 

Комплетан репозиторијумГрупеАуториНасловиТемеОва институцијаАуториНасловиТеме

Статистика

Преглед статистика

DSpace software copyright © 2002-2015  DuraSpace
О ФарФаР-у | Пошаљите запажања

OpenAIRERCUB